ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2673

Mortality In Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With The General Population

Aleksandra Turkiewicz1, Tuhina Neogi2, George Peat3 and Martin Englund4, 1Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Research Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom, 4Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality, osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis I: Therapeutics in Osteoarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is strong evidence in support of increased mortality in patients with rheumatoid arthritis (RA), while the relation is more controversial in osteoarthritis (OA). Our aim was to assess mortality rates in patients with clinically relevant OA and RA, respectively, compared with those in the general population who have sought health care to minimize confounding.

Methods: We used a cohort study design within the Skåne Health Care Register in Sweden, which is a legislative, mandatory register based on physicians’ International Classification of Diseases (ICD) 10 diagnostic codes. The register covers all primary and specialist health care as well as hospitalizations in southern Sweden (population 1.3 million). The Swedish population register contains information about vital events (births, deaths) and changes in residential address. We identified all patients aged ≥45 years having received the diagnosis of knee OA (ICD-10: M17), hip OA (M16), hand OA (M18, M15.1, M15.2, M19.0D, M19.1D, M19.2D), or RA (M05, M06) during 1999 to 2006. For RA patients we required at least two health care visits with the specific code registered, with at least one from a specialist in rheumatology or internal medicine. For OA we required at least one visit with the specific code registered. For the reference population aged ≥45, we required at least one visit with any diagnostic code (90% of the population had sought care during the period). Using the population register we followed all subjects from Jan 1st 2007 until relocation outside of the region, death, or Dec 31st 2011. We calculated mortality rates using the Cox proportional hazard model adjusted for age and sex, disposable income, marital status, and highest level of education reached (provided by Statistics Sweden). In a sensitivity analysis, we considered subjects who received a diagnosis of pain in a joint (M25.5, location unspecified) at age 55 or older as OA subjects in addition to the definition above.

Results: The hazard ratio of death for RA patients compared to general population was 1.58 (95% CI: 1.35-1.84). Patients with knee, hip or hand OA did not have increased risk of mortality compared with the general population, adjusted for age, sex and socioeconomic variables (Figure). The risk of death remained similar when OA in any joint (i.e., any combination of knee, hip, or hand) was assessed, or when pain in a joint at age ≥55 was additionally considered as OA. Effect estimates were similar in men and women (Table).

Conclusion: We found no evidence of increased risk of mortality over 5 years in patients with doctor-diagnosed knee, hip or hand OA, compared with the general population, while increased mortality in RA was confirmed.


Disclosure:

A. Turkiewicz,
None;

T. Neogi,
None;

G. Peat,
None;

M. Englund,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-in-clinically-relevant-osteoarthritis-and-rheumatoid-arthritis-compared-with-the-general-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology